Edward Poon

Associate

Disclaimer

Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Edward Poon focuses his practice on corporate finance and capital markets. His experience includes advising on Hong Kong initial public offerings, cross-border mergers and acquisitions, regulatory compliance, and general commercial matters.

Languages

  • Mandarin
  • Cantonese

Admissions

  • Hong Kong

Education

  • University of Hong Kong, PCLL; LLB

ECM Transactions

  • Beauty Farm Medical and Health Industry Inc. in its approximately US$100 million IPO and listing on the Hong Kong Stock Exchange
  • Yonghe Medical Group Co., Ltd. in its US$206 million IPO and listing on the Hong Kong Stock Exchange
  • Goldman Sachs (Asia) L.L.C. and China International Capital Corporation Hong Kong Securities Limited and other underwriters in the US$145 million IPO and listing of Shanghai HeartCare Medical Technology Corporation Limited on the Hong Kong Stock Exchange
  • Keymed Biosciences Inc. in its US$398 million IPO and listing on the Hong Kong Stock Exchange
  • Fortune Financial Capital as sole sponsor, Fortune Securities, CICC as joint global coordinators and other underwriters in the US$56.8 million primary listing of Zero2IPO Holdings Inc. on the Hong Kong Stock Exchange
  • J.P. Morgan, BofA Securities, CICC and Haitong International as joint sponsors and other underwriters in the approximately US$1.67 billion secondary listing of GDS Holdings Limited on the Hong Kong Stock Exchange
  • Akeso Biopharma in its US$383 million IPO and listing on the Hong Kong Stock Exchange
  • Pharmaron in its approximately US$588 million dual primary listing and H share offering in Hong Kong
  • Viva Biotech in its US$194 million IPO on the Main Board of the Hong Kong Stock Exchange
  • Hua Medicine in its US$110 million IPO on the Main Board of the Hong Kong Stock Exchange
  • China Securities International as the sole sponsor and sole global coordinator in FingerTango’s US$133 million IPO on the Main Board of the Hong Kong Stock Exchange
VIEW MORE

Press Releases

O’Melveny Advises Acotec Scientific on the First Takeover Offer to a Chapter 18A Biotech Company

February 13, 2023

O’Melveny Represents Beauty Farm in US$100 Million Hong Kong IPO

January 16, 2023

O’Melveny Completes China VAST Going Private Transaction

December 7, 2022

O’Melveny Represents Central China Real Estate and its Controlling Shareholder in US$83 Million Share Sale

August 12, 2022

O’Melveny Represents China VAST in Going Private Transaction

June 15, 2022

O’Melveny Advises Global Infrastructure Solutions Inc. in Strategic Merger with J. Roger Preston

May 31, 2022

O’Melveny Represents Yonghe Medical in US$192 Million Hong Kong IPO

December 13, 2021

O’Melveny Represents Underwriters in Hong Kong IPO of Shanghai HeartCare Medical Technology Corporation Limited

August 20, 2021

O’Melveny Represents China VAST and its Major Shareholder in US$314 Million Share Sale and Convertible Bond Subscription by China Jinmao

July 19, 2021

O’Melveny Represents Keymed Biosciences in Approximate US$400 Million Hong Kong IPO

July 8, 2021

In the News